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7Foreword 
The daily work of physicians includes a constant flow of information: diagnostic tests 
or drugs that are marketed for various and sometimes changing indications, and new 
and/or rare clinical diagnoses that should be noticed or unexpected manifestations of 
already well-known diseases that need to be acknowledged. Physicians also need to 
keep up with a large number of continuously changing regulations regarding the 
social aspects of health care. In this context, it is understandable that laboratories can 
experience difficulties informing physicians about the introduction of new laboratory 
tests or about changes in the use of well-known tests, which could involve changes 
regarding when or how to perform the test or how to interpret the results. Given that 
the correct diagnosis and follow-up of patients will ultimately always be the 
responsibility of that patient’s physician, what is the responsibility of the laboratory? 
There are of course many answers to this question, but the data presented in this 
dissertation focuses on one main aspect: the responsibility of the laboratory to help 
physicians to choose the best available test procedures, and to get the most out of the 
information provided by the test results, thereby facilitating the correct diagnosis and 
follow-up of patients. 
 During recent years the indications for some renal parameters have changed, 
and new tests have been introduced to facilitate the earlier diagnosis of renal disease 
(e.g. albumin:creatinine ratio and estimated glomerular filtration rate). Common 
practice is to implement such changes only after limited information programmes and 
to report laboratory results without comments. We chose to investigate how these 
tests are used and interpreted in the primary health-care setting. Our findings may be 
generally applicable to situations where changes in other laboratory analyses are 
implemented in similar ways. After investigating current practices and the possible 
consequences of misinterpretations, we have been able to introduce some initiatives 
that may improve laboratory practice and the understanding of laboratory test results 
in the future, making information more accessible to physicians. 
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Aims: Chronic kidney disease (CKD) affects approximately 10% of the adult 
population. CKD patients have increased risks of morbidity and mortality, mainly 
from cardiovascular end points; early diagnosis and treatment is therefore warranted. 
CKD may be diagnosed based on an estimated glomerular filtration rate (eGFR) that 
is calculated from creatinine data, and the prognosis may be predicted based on 
urinary albumin excretion. The aim of this work was to elucidate how urinary 
albumin and eGFR are used and interpreted in the primary health-care setting. 
Another focus was to assess how the clinical chemistry laboratories that usually offer 
these tests interpret the test results. 
Methods: In all four studies, data were collected with the aid of a questionnaire. For 
Articles I and II, 10,000 general practitioners in 11 countries received a case-history-
based questionnaire depicting a male type 2 diabetes patient. For Article III, 386 
physicians received a questionnaire asking about 1 of their patients (selected from 2 
different hospital laboratory databases) who had been diagnosed with CKD stage 3, 
based on eGFR results. For Article IV, 100 laboratory specialists in Norway and the 
Netherlands received a questionnaire regarding 2 case histories from primary health 
care (hypertensive and diabetic patients with laboratory results signalling possible 
renal disease) and 1 from a hospital setting. 
Results: The studies described in Articles I and II included 2078 general practitioners 
from 9 European countries. Almost all of the general practitioners recommended 
annual microalbuminuria testing in diabetic patients, whilst a lower frequency of 
testing was suggested for patients with hypertension or possible CKD. A spot urine 
sample prevailed for first-time office-based testing, whilst timed collections were 
used to a larger extent for hospital-based repeat testing. Of the 2078 general 
practitioners, 62% requested a repeat test to confirm the diagnosis if the first test was 
positive. Median values for the critical difference in albumin values was 33%, and 
four different measurement units were used. The absolute increase in the percentage 
of general practitioners who would supplement the patient’s drug treatment if 
9microalbuminuria developed was 23–50% (depending on the country) for 
angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers 
(ARBs), 0–19% for statins, 2–13% for acetylsalicylic acid and 0–33% for 
hypoglycaemic agents (tablets and insulin). For Article III, the response rate was 
60%, and 210 patients were included. The median creatinine values were 95 and 
124 μmol/l for female and male patients; the corresponding eGFR values were 52 and 
51 ml/min/1.73m2. Only 27% of patients were assessed to have CKD stage 3. Two-
thirds had a urine dip strip (59%) and/or a urinary albumin (42%) measurement, and 
20% were diagnosed with albuminuria (including both micro- and 
macroalbuminuria). Median changes to signal improvement or deterioration in renal 
function or indicating need for referral were 14 (12%), 20 (18%), and 40 (36%) 
μmol/l, respectively, for creatinine, and 8 (17%), 8 (17%) and 
13 (26%) ml/min/1.73 m2 for eGFR. Albuminuria did not influence the follow-up 
strategy. For Article IV, 52 (52%) laboratory specialists responded. Based on 
guideline recommendations, less than 30% would suggest an optimal test panel for 
evaluating renal function in the two primary-care patients. For creatinine and eGFR, 
the median changes considered to signal improvement or deterioration in renal 
function (creatinine, 14% and 14%, respectively; eGFR, 18% and 13%, respectively) 
were similar to what could be calculated using information on analytical and within-
subject variations from the literature. The albumin:creatinine ratio varied (median 
values: 50% for improvement and 67% for deterioration). 
Conclusions: Guidelines for diagnosing microalbuminuria are only partially followed 
by general practitioners, and should be made more practicable, addressing issues such 
as type of samples, measurement units and repeat tests. Intensified drug treatment, 
and especially increased use of ACEIs and ARBs, was recommended to diabetic 
patients when microalbuminuria was present. CKD stage 3 patients were 
insufficiently examined for albuminuria and seemingly referred to hospital care only 
after the eGFR declined more than recommended in guidelines. Renal parameters are 
interpreted differently by laboratory specialists, and this could result in different 
advice being offered to clinicians, which again may affect patient care. 
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INTRODUCTION 
The following second-level sections provide the background on chronic kidney 
disease (CKD), biological variations and critical differences (CDs), and describe the 
use of biomarkers in renal disease, with special emphasis on measurements of urinary 
albumin and the estimated glomerular filtration rate (eGFR). Furthermore, how 
laboratories communicate with clinicians and how questionnaires may be used as a 
research tool are discussed. 
Chronic kidney disease 
Definition of chronic kidney disease 
CKD is defined by the patient’s glomerular filtration rate (GFR) and markers of renal 
injury, and according to the Kidney Disease Quality Outcome Initiative classification 
may be divided into five different stages (Table 1) (1). This classification system has 
now been adopted by most medical societies (2-7). Stages 1 and 2 require urine 
examination for albuminuria, proteinuria or haematuria, whilst stages 3–5 are defined 
only by GFR values. GFR measurements should be obtained on two occasions 
separated by at least 3 months when determining whether to classify the condition as 
chronic. Stage 5 is defined as end-stage renal disease (ESRD) or kidney failure, and 
usually requires dialysis therapy. 
Table 1. Definition and staging of CKD. 
Stage Description GFR (ml/min/1.73 m2)
1 Kidney damage* with normal or increased 
GFR 
90 
2 Kidney damage* with mild reduction in GFR 60–89 
3 Moderate reduction in GFR 30–59 
4 Severe reduction in GFR 15–29 
5 Kidney failure (ESRD) <15 (or dialysis) 
*Defined as albuminuria, proteinuria, haematuria, or anatomical abnormality 
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The CKD classification system has been criticized for not being sufficiently accurate 
and labelling patients without progressive kidney disease as having moderately 
reduced renal function (8, 9). Even if a rapid decline in GFR (a decrease over 1 year 
of 4–5 ml/min/1.73 m2) signals a worse prognosis of CKD, the course of the disease 
may usually be predicted by the finding of albuminuria or proteinuria (10-13) that is 
seen in approximately 30% of CKD stage 3 patients (14). It has therefore been 
suggested that albuminuria assessment should be included in the classification of 
CKD (15, 16) for the purpose of targeted follow-up and treatment of patients at 
higher risk. eGFR values in the range of 50–60 ml/min/1.73 m2 are quite common in 
healthy subjects older than 70 years (9). Thus, it has also been suggested that stage 3 
should be subdivided into two stages, 3A (GFR 45–59 ml/min/1.73 m2) and 3B (GFR 
30–44 ml/min/1.73 m2), which could yield more information in epidemiological 
studies (17) and better differentiate between patients with a stable low renal function 
and those at greater risk of progressive renal disease. 
Epidemiology of chronic kidney disease 
Recent studies have shown CKD to be far more common in the adult population than 
was previously expected. More than 10% of the adult population may be affected (14, 
18), and newer data suggest that the prevalence is increasing (19, 20). Most patients 
(about 50%) are classified as CKD stage 3. The prevalence of CKD increases with 
age and is more frequent among females (21), whilst the dialysis departments are  
frequently populated by males (22, 23). Important risk factors for developing CKD 
are hypertension (24), which affects most patients at CKD stage 3 or lower, and 
diabetes, which affects 10–20% of the overall CKD population (21). Cardiovascular 
disease (CVD) is found in 15–50% of CKD patients (21, 25, 26), with the prevalence 
increasing as renal function deteriorates. The risk of developing ESRD is much lower 
than the mortality risk during the course of the disease (10); one study found that only 
1% of CKD stage 3 patients progressed to renal replacement therapy during a 5-year 
follow-up, whilst 24% died during the observation period (27). A British study 
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showed that 4% of patients with creatinine levels of 150 μmol/l developed ESRD 
during a 5.5-year follow-up, whilst 69% died during the observation period, mostly 
from cardiovascular end points (28). Even so, 700–800 adults per million of the 
European population receive renal replacement therapy (i.e. dialysis, haemofiltration 
or transplantation), and the incidence is increasing (22, 23). 
Renal disease in diabetes 
Diabetes is a chronic disease whose prevalence is increasing rapidly. The World 
Health Organization estimates that by 2030 about 350 million people worldwide will 
suffer from the disease, and mainly type 2 diabetes (29). Diabetic patients are at 
increased risk of CVD and microvascular complications, retinopathy, neuropathy and 
nephropathy. The prevalence of diabetic nephropathy is related to the duration of 
diabetes and glycaemia control, and reportedly lies in the range 12–40% (30, 31). 
Diabetic nephropathy is defined as albuminuria (i.e. a raised urinary albumin 
excretion above 300 mg/day), corresponding to an albumin:creatinine ratio (ACR) of 
approximately 30 mg/mmol; renal damage is considered to be irreversible at this 
stage. To facilitate earlier diagnosis and treatment, and thereby prevent diabetic 
nephropathy from developing, annual screening to detect lower concentrations of 
urinary albumin (30–299 mg/day) has been recommended for decades (32). A low 
concentration of urinary albumin (often referred to as microalbuminuria) is an 
independent predictor of CVD and ESRD (33), but the risks are reduced if adequate 
treatment is provided, mainly by reducing blood pressure and lowering blood glucose 
(34-36). This is further discussed later in this dissertation (see page 25, 
“Interpretation of urinary albumin results”). 
19
Screening for chronic kidney disease 
The early stages of renal disease cause few and vague symptoms, and most CKD 
patients will therefore not seek medical treatment (37). General screening 
programmes or screening in high-risk populations have been discussed, and current 
guidelines recommend eGFR and urinary albumin (or protein) examinations in 
patients with hypertension, diabetes, CVD or at risk of CVD, and in patients with a 
family history of CKD (4-6, 38-43).  
 There are several benefits of diagnosing CKD at its early stages (i.e. stages 1–
3): the patients may receive intensified treatment for hypertension and 
hyperglycaemia (diabetic patients), and complications (i.e. anaemia and bone-related 
renal disease) (6) may be treated earlier. Monitoring urinary albumin is useful for 
guidance during the follow-up period (6, 44-47). Mortality rates are 10–20 times 
higher among dialysis patients than in the general population (48); 20–30% of 
patients are referred to nephrology care less than 90 days before starting dialysis (22, 
49), and it has been shown that late referral is a risk factor that can increase mortality 
even further (50). CKD patients are at increased risk of developing acute renal failure 
during acute illness. If CKD is not recognized delayed renal protective treatment in 
these situations may lead to a permanent need for renal replacement therapy (51). 
Earlier identification of CKD is therefore an important issue both for the individual 
patient and for society. Targeted surveillance aims at delaying the progression of 
renal disease and reducing the associated mortality, morbidity and the need for renal 
replacement therapy (6, 34-36), leading to improved quality of life and a reduced 
financial burden on the health-care system. 
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INTERPRETATION OF CHANGES IN LABORATORY 
TEST RESULTS 
Biological variation 
Biological variation is defined as natural fluctuations in the concentrations of 
constituents around a homeostatic set point, and both the within-subject biological 
variation (CVi) and between-subject biological variation (CVg) may be calculated 
based on data from repeated sampling. Data on the biological variations for different 
biomarkers have been published (52) and are also available on Westgard’s homepage 
(53). Even so, these data need to be interpreted with caution, since not all have been 
obtained using a strict methodology (54). It is therefore crucial that reports on 
biological variations strictly define the methods used to obtain the data (e.g. exclusion 
of outliers, tests for homogeneous variances and pre-analytical conditions such as 
sampling time, posture, centrifugation, type of specimen used, time of measurement 
and storage of the samples before measurement). 
 Biological variation can be used to define analytical quality specifications, 
calculating the CD (see below for further explanation) between follow-up results and 
for calculating the index of individuality to determine whether population-based 
reference values are suitable for detecting pathological changes (55). The index of 
individuality is defined as CVi/CVg; values lower than 0.6 are normally indicative of 
a large population-based reference range, which are of lesser value as action limits for 
detecting pathological results in individual patients; therefore, CD values may be 
used instead. When the index of individuality exceeds 1.4 (corresponding to a large 
CVi and small CVg, comparison with reference ranges is more likely to reveal 
significant changes in patients’ test results, and so this parameter is considered more 
useful. Between these two cut-off values is a grey zone wherein both the application 
of reference ranges and CD values may be useful for defining action limits. 
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Critical difference and diagnostic cut-off values 
Clinically important changes in biomarker concentrations may be evaluated using the 
concept of CD described by Fraser and Harris in 1989 (55). The CD is defined as the 
minimum difference needed between two consecutive results to be certain (with a 
specified level of confidence, z) that the results are truly different, and that the 
difference is not only due to analytical variation (CVa) and CVi (55): 
222 CViCVazbiasCD +××+=
The value of z defines the level of confidence when calculating the CD. The bias
value denotes differences due to samples being analysed at different times (e.g. due to 
calibrations or different reagent lots) and may be included in the CVa (imprecision 
under reproducibility conditions). It is important to emphasize that the CD value only 
provides a measure for judging the probability that a change between consecutive 
results may be explained on the basis of CVa and CVi for a patient in a stable 
situation; it does not provide a measure with which to judge the probability that a true 
change (deterioration or improvement) has occurred. It is important to take both of 
these aspects into account when fully evaluating the difference between two results 
(56). 
BIOMARKERS IN CHRONIC KIDNEY DISEASE 
Biomarkers in renal disease may be divided into two categories: (i) those measuring 
GFR and (ii) those detecting renal injury through urine analysis. GFR is measured as 
the renal clearance (i.e. measurement of the rate of renal filtration of a substance 
freely filtered by the glomerulus and not excreted or reabsorbed in the renal tubules). 
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The gold-standard clearance method used to be that of inulin. This is a cumbersome 
procedure involving several serum and urine samplings and has for practical purposes 
been replaced by simpler methods whose results correlate strongly with inulin 
clearance. Examples are the clearances of iohexol and iothalamate (contrast media), 
and of 51Cr-EDTA and 99Tc-DPTA (radioisotopes) (57, 58). Formulas that correct for 
the extracellular distribution of the injected substance are normally used when 
calculating the results (59, 60), so that only one blood sample needs to be obtained 
after injecting the substance. Even though the procedure has been simplified, it is still 
invasive and usually only used when precise GFR measurements are needed (e.g. 
when evaluating kidney donors or patients receiving nephrotoxic drugs for a long 
time) (5, 6). The GFR may also be calculated (i.e. estimated) based on concentrations 
of in-vivo biomarkers for renal disease; a more detailed description of such 
algorithms is given later in this dissertation (See page 26, “Estimating the glomerular 
filtration rate”). 
 The common method for evaluating renal function in primary health-care and 
most hospital settings is the measurement of different metabolites produced in vivo, 
freely filtered by the glomerulus and then to various degrees reabsorbed or excreted 
in the renal tubules. Such parameters are influenced by different physiological 
processes and therefore can be inaccurate measures of renal function. Creatinine is 
produced at fixed rates, since 1–2% of creatine phosphate in muscle is converted into 
creatinine daily, and therefore the actual amount of creatinine produced (i.e. the 
concentration of creatinine) will vary greatly between subjects due to differences in 
muscle mass. In addition, decreases in renal function lead to increased excretion of 
creatinine in the renal tubules. Urea is produced during protein metabolism, and its 
concentration is influenced by diet, malignancy, drugs, tissue hypoxia, metabolic 
acidosis and intoxication with alcohol or lead. It is moderately correlated with 
symptoms of severe CKD and is therefore usually used for evaluating ESRD. It may 
also be used to distinguish between prerenal and post-renal causes of uraemia. 
Cystatin C is produced in all nucleated cells and is less influenced by factors not 
related to renal function. Its use has been recommended in certain subpopulations, but 
23
the assay is not standardized and has not been shown to be superior to either 
creatinine measurements when used as a screening tool in the general population (61) 
or creatinine-based eGFR calculations in subjects with a lower muscle mass (62). 
However, newer research has indicated that cystatin C might be a better predictor of 
progressive renal disease, since creatinine yields only limited information on this 
important issue (63). 
 Biomarkers in urine are measured for the earlier detection of renal injury or for 
prognostic assessments, and measurement of total urine protein using a dip-strip test 
has been a popular screening test for many years. The test strips usually react to 
albumin at concentrations greater than 150 mg/l, but they also react to other kinds of 
urinary proteins and may therefore yield limited information on pathological 
processes within the kidneys. More recently, urinary protein measurements have been 
replaced by more sensitive and quantitative tests that are specific for different 
proteins. For example, urinary albumin and immunoglobulin-G measurements are 
useful for detecting injury to the renal glomerulus, whilst elevated levels of alpha-1-
microglobulin or beta-2-microglobulin indicate tubular damage (58). 
 While test strips may become less popular for identifying albuminuria, they are 
still used for detecting haematuria, such as that seen in urological cancer and 
glomerulonephritis. Microscopy analysis of urine is also useful in the latter condition 
for identifying specific blood cell casts, but further discussion of these methods is 
beyond the scope of this dissertation. 
URINARY ALBUMIN 
Methods and reporting procedures currently in use 
The methods and procedures that are capable of accurately measuring low 
concentrations of urinary albumin (microalbuminuria) have been discussed for 
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decades (Table 2). Nephropathies are defined by the 24-hour excretion of albumin (or 
sometimes total proteins) in urine, but since this is a cumbersome and often 
inaccurate method, several surrogate measuring procedures exist. These methods 
include 4- to 12-hour urine collections and measurement of the urinary albumin 
excretion rate per minute. At present, the use of spot samples is common, with or 
without corrections for differences in urine concentration by measuring urine 
creatinine and calculating the ACR or protein:creatinine ratio. The ACR correlates 
acceptable with results from 24-hour collections (64) and is an often-favoured test (5, 
6, 39, 45). Still, guidelines do not always give clear advice on the best procedure for 
measuring urinary albumin (54), and currently four different measuring procedures 
exist (Table 2: mg albumin/24 hours, μg albumin/min, mg albumin/l and mg 
albumin/mmol creatinine). The diagnostic cut-offs vary between countries (44, 45, 
65-67), and a clear differentiation between albuminuria and proteinuria is sometimes 
lacking when this topic is discussed (65). 
Table 2. Different procedures and cut-off values (range) for defining pathological 
urinary albumin (rows 1–3) or protein (row 4) concentrations (44, 45, 65-67). 
24-hour collection 
(mg/24 hours) 
Timed 
collection 
(μg/minute) 
ACR or 
protein:creatinine ratio 
(mg/mmol) 
Albumin 
concentra-
tion (mg/l) 
Normal <30 <20 <2.0 to <3.4a <20b
Microalbuminuria 30–299 20–199 2.0–3.4
a
(lower range) 
19.9–33.9a (upper range) 20 
Albuminuria 300 200 20 to 34a  
Proteinuriac 300 to 500a  30 to 50a Positive dip strip 
aRange of different cut-offs that are used 
bA clear cut-off is not defined 
cMeasuring total urinary protein 
 Due to the large biological variation that occurs irrespective of the 
measurement procedure (54), current recommendations state that an elevated urinary 
albumin result should be confirmed within 1 week to 6 months, and at least two out 
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of three results should be above the diagnostic cut-off before microalbuminuria is 
diagnosed (44-47, 68). Albumin excretion varies during the day, and may be higher 
after physical activity. Morning samples are therefore recommended for analysing the 
ACR or albumin concentration. Point-of-care testing (POCT) instruments with good 
analytical quality are available (69, 70), and testing may therefore be performed both 
in hospital laboratories and the offices of general practitioners (GPs). Dip-strip tests 
that are sensitive to low concentrations of albumin are also used, but the results are 
more difficult to interpret since values are reportedly qualitative, and the analytical 
performance is variable. 
Interpretation of urinary albumin results 
Urinary albumin is elevated in up to 10% of the general population and is correlated 
with increased risks for CVD and ESRD (13, 71-73). To prevent the progression of 
renal disease, angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II 
receptor blockers (ARBs) are recommended in all CKD and diabetic patients with 
albuminuria (40, 41, 44-47); blood pressure control based on ACR values is also 
suggested (6, 44-47). Diabetic patients with albuminuria should have intensified 
treatment of risk factors for macro- and microvascular disease; that is, increased use 
of statins and acetylsalicylic acid (ASA) and a lower Hba1c threshold than the often-
suggested value of about 7% (44-47). 
 When urinary albumin results are used for monitoring the progression of renal 
disease it might be difficult to interpret when changes in serial results are of clinical 
significance. A recent review article evaluating 25 studies on biological variation 
found large variations in reported CVi values, both between and within the different 
methods. The lowest variation was seen for ACR measurements (54). Aggregating 
these data provides an estimate of the CVi and CD values that may be expected using 
different urinary albumin measurements (Table 3) (54). 
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Table 3. An overview of CVi values obtained in 25 different studies (54), listing the 
overall 25th, 50th and 75th percentiles for the CVi of different procedures and the 
corresponding CD value (two-sided test, 95% confidence interval, CVa of 5%). 
n=number of reported CVi values. 
CVi (%) CD (%) 
n 25th percentile 
50th 
percentile 
75th 
percentile 
25th 
percentile 
50th 
percentile 
75th 
percentile 
24-hour 
collection 16 21 36 49 85 142 193 
Timed collections 20 32 41 56 127 162 220 
ACR 34 25 34 50 100 135 197 
Urinary albumin 
concentration 22 27 41 60 108 162 236 
ESTIMATING THE GLOMERULAR FILTRATION RATE 
Development of formulas for estimating glomerular filtration rate 
In-vivo biomarkers for renal function such as creatinine and cystatin C are affected 
by factors other than GFR (74), and this may lead to delayed identification of renal 
disease in certain populations. Several formulas that have been developed to 
compensate for this are based on the correlation between the measured GFR and the 
average value of one or more biomarkers found in different subpopulations. The first 
formula used was that described by Cockcroft and Gault in 1976 (75), which included 
age, gender and body weight in the calculations. The Modification of Diet in Renal 
Disease (MDRD) formula was developed recently (76), based on age, gender and 
ethnicity. This formula shown an acceptable correlation with measured GFR values 
up to 60 ml/min/1.73 m2 (77), is standardized to different creatinine assays (78) and is 
easy to report automatically since age and gender information can be obtained from 
the patient’s social security number. This is currently the most frequently used 
formula for adult populations, but there are also several other formulas available both 
for adults and children (79-83). 
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Recommended use and interpretation of MDRD-based estimated 
glomerular filtration rate results 
MDRD-based eGFR values are used for diagnosing (classification and staging) and 
monitoring renal disease. They are easy to obtain and more accurate than some of the 
more cumbersome methods (e.g. creatinine clearance) (84-86). This makes the 
screening of large populations possible, and it has been shown that reporting eGFR 
values facilitates the early diagnosis of renal disease (87-89) and can be used for drug 
dosing (90). The current recommendations are that eGFR values should be reported 
automatically with all creatinine results (3-6, 38). 
 eGFR reporting still has certain limitations. First, the label “eGFR” may 
mislead physicians into thinking that this is a more advanced GFR measurement than 
just an age- and gender-adjusted creatinine value. eGFR values have an overall 
negative bias of 6% relative to GFR measurements by renal clearance, and only about 
80% of estimated values fall within ±30% of the measured GFR (77). This implies 
that for a measured GFR value of 50 ml/min/1.73 m2, there is an 80% chance that the 
corresponding eGFR value would lie in the range 35–65 ml/min/1.73 m2. Pre-
analytical factors such as diurnal variations (91), ingestion of cooked meat (92, 93) 
and biological variation of creatinine (94) may explain some of the inaccuracy 
associated with eGFR results, but most of it is probably related to differences in 
muscle mass between subjects, which are only partly compensated for. The available 
guidelines do not usually emphasize the clinical situations in which eGFR results are 
regarded as being sufficiently accurate for clinical decision-making, and when 
measured GFR examinations are necessary (3, 5, 38). 
 Second, the formula used has not been validated for many populations (e.g. 
different ethnic groups, pregnant woman, critically ill patients and Fabry disease), 
and yet values are still reported automatically and may often be interpreted by 
clinicians as valid measures (95, 96). 
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 Third, a common recommendation is that exact values should only be reported 
for CKD stages 3–5, since the formula does not provide sufficiently accurate values 
at higher levels, and such results are usually reported as >60 ml/min/1.73 m2. 
Physicians may therefore take 60 ml/min/1.73 m2 to be the lower limit of the 
reference range or the action limit for CKD, and further investigations including 
urinary albumin measurements might not be performed leading to delayed diagnosis 
of patients with CKD stage 1 or 2. 
Many diabetes and CKD guidelines recommend annual eGFR monitoring (5, 
6, 40, 41, 43) to identify progression in renal disease, but often give little information 
on the magnitude of differences that might be expected in subsequent eGFR results 
(2, 4, 5). One guideline suggests that a 6-month 15% decline in GFR is clinically 
significant (3), whilst others suggest that a 1-year decrease of 4 ml/min/1.73 m2 is 
rapid (2), and yet others emphasize that a CVi of 5% should be expected for 
creatinine values, but do not suggest the degree of change that can be anticipated for 
consecutive eGFR measurements (6). Guidelines recommend that patients with CKD 
stage 4 or 5 should be referred to nephrology care (3, 6), but for stage 3 patients the 
advice varies, from a 1-year decline of 5 ml/min/1.73 m2 (6) to a 6-month 50% 
decrease (3) in eGFR values. 
COMMUNICATION BETWEEN LABORATORIES AND 
CLINICIANS 
Laboratories communicate with clinicians through the test repertoire they offer, the 
lay out of request forms (97, 98), reporting of commented or uncommented test 
results (87, 99, 100), occasional personal contact with physicians, laboratory 
newsletters and educational programmes arranged by the laboratory (88, 101). 
Specialists in laboratory medicine working in clinical chemistry laboratories are 
involved in the implementation of new test procedures and may, according to the 
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International Standard for Accreditation of Medical Laboratories (ISO 15189), be 
expected to advise clinicians on the interpretation of test results. Interpretive 
commenting of new or complicated tests can be valuable (87, 102) and is greatly 
appreciated by physicians (103). The information provided to clinicians from the 
laboratory is usually based on the laboratory professionals’ experience with analytical 
procedures and the literature, including textbooks, scientific articles and guidelines. 
 Some challenges related to this practice should be acknowledged. First, there 
is general a large amount of scientific literature related to the use of different kinds of 
laboratory analyses and interpretation of results, and this information is sometimes 
conflicting. Furthermore, low-quality information may be prominent (e.g. opinion 
papers, consensus statements and non-peer-reviewed papers), and if these 
publications are not in agreement with scientific findings they might lead to 
suboptimal practice. The scientific literature for other topics, such as request forms 
and algorithms for reporting of results, may be scarce. Several articles have shown 
that the quality of guidelines might be low (104-106) and that many 
recommendations are based on consensus or low-quality evidence (107). As a 
consequence, the laboratory professional may focus on different aspects, reach 
different conclusions and give different advice, which is highly likely to lead to 
diverse and sometimes low-quality laboratory practices (108-110). Studies have 
shown that the commenting of laboratory results by laboratory professionals may also 
be of variable quality (111-113), even for common laboratory tests including renal 
parameters (114). It may be anticipated that the laboratories performance related to 
these issues may have impact of follow-up and treatment of patients. 
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AIMS OF THE STUDY 
The main aim of this work was to elucidate the use and interpretation of urinary 
albumin and eGFR in primary health care and relevant advices offered by laboratory 
specialists. We also aimed to uncover some of the consequences of misinterpretation 
of such test results. The detailed aims of this study were as follows:
• To determine the use and interpretation of urinary albumin testing in primary 
health-care in different regions of Europe, with emphasis on the availability of 
equipment in the physician’s office and what changes in urinary albumin results 
GPs considered clinically important (Article I). 
• To compare GPs’ knowledge of urinary albumin testing with guideline 
recommendations in patients with type 2 diabetes, and how the presence or 
absence of microalbuminuria influences drug treatment (Article II). 
• To examine how CKD stage 3 patients are investigated and treated in primary 
health care, with special emphasis on the use of creatinine, eGFR and urinary 
albumin, and what changes in creatinine and eGFR results that were considered 
clinically important by GPs (Article III). 
• To explore what advice laboratory specialists would give to clinicians, focusing 
on three aspects: (i) what further testing should be recommended in primary 
health care for a diabetic or hypertensive patient after obtaining laboratory results 
suggesting possible renal damage, (ii) what changes in eGFR and ACR results 
should be considered clinically significant, and (iii) the extent to which laboratory 
specialists anticipate uncertainty of MDRD-based eGFR results (Article IV). 
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SUMMARY OF ARTICLES 
ARTICLES I AND II – ANALYTICAL AND CLINICAL 
ASPECTS OF URINARY ALBUMIN MEASUREMENTS 
IN PRIMARY HEALTH CARE 
Subjects and methods 
A case-history-based questionnaire was posted to approximately 10,000 GPs in 10 
European countries and Australia. Since urinary albumin examination is probably 
most established for diabetic patients, a case history was formulated based on the 
profile of a male type 2 diabetic patient in whom urinary albumin testing had not 
been performed (see Appendix 1), and questions were posed related to diagnosing 
microalbuminuria, and follow-up and treatment of the patient. Clinically important 
changes in urinary albumin results were evaluated. Assuming long-term random bias 
(e.g. due to calibrations of different reagent lots to be included in the CVa), the 
anticipated CVa was calculated for the ACR using a CVi of 24% (year-to-year 
variation) (115) and z values of 1.64 and 0.84 reflecting confidences of 95% and 80% 
(one-sided test), respectively. A four-page feedback report was translated into the 
native languages of the recipients and sent to all participants including an update on 
the laboratory and clinical implications of microalbuminuria (see Appendix 2). 
Results: Article I 
In total, 2078 GPs from 9 countries were included in the study described in Article I, 
and the response rate varied from 7% to 43% depending on the country, with the 
availability of in-office testing ranging from 4% to 88%. For a first-time examination 
for microalbuminuria, GPs in most countries preferred to use morning or random 
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urine samples rather than timed collections. Overall, 62% of GPs stated that they 
would repeat the testing in order to confirm a positive result. Differences in the use of 
test materials were related to in-office equipment: for first-time examination, 95% of 
GPs with in-office testing and 70% of GPs without in-office testing used morning or 
random urine samples, while for repeat tests 63% of semi-quantitative strip users, 
31% of quantitative albumin measurement users and 16% of ACR users preferred a 
repeat test to be done in a larger laboratory. When such a laboratory was used for 
follow-up tests, the use of timed samples was high, and similar between GPs with or 
without in-office testing (64% vs 57%). In all but one country, all four measurement 
units were used when CDs were stated. The median CDs for the estimation of a 
clinically significant increase or decrease in urinary albumin were similar in most 
countries (30–35%). CD did not vary with the unit category that was reported. The 
median CVa values required to meet the clinical CD requirements with 80% 
confidence were similar (at about 14%) in most countries for both an increase and 
decrease in ACR values. 
Results: Article II 
Almost all of the GPs who responded in the study described in Article II would 
request urinary albumin for diabetic patients, whereas fewer would use it to evaluate 
patients with hypertension or renal disease. The availability of in-office methods for 
urinary albumin seemed to broaden the indications for the test. Negative and positive 
test results appeared to be followed up with a new test after 6–12 and 1–3 months, 
respectively. Drug treatment would be supplemented by 61–91% of GPs in the 
various countries if the patient was normoalbuminuric, and nearly 100% would do so 
if the patient had microalbuminuria, mainly by adding statins and ACEIs or ARBs. 
The proportion of GPs recommending all four treatment alternatives [grouped as 
ASA, blood glucose-lowering agents (insulin and oral hypoglycaemic agents), 
antihypertensives and statins] was low, but increased by 8–12% when the patient had 
microalbuminuria.
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ARTICLE III – INVESTIGATION OF CHROINC KIDNEY 
DISEASE STAGE 3 IN PRIMARY HEALTH-CARE 
Subjects and methods 
The patients and GPs were selected by searching laboratory databases for creatinine 
results obtained in 2008 at the two university hospitals in the Norwegian cities of 
Bergen and Stavanger. The search criteria were primary-care patients between 40 and 
70 years of age who had two eGFR results requested by the same GP (more than 
3 months apart) that did not differ by more than 5 ml/min/1.73 m2 and ranged 
between 30 and 59 ml/min/1.73 m2 (corresponding to CKD stage 3). 386 physicians 
had received creatinine and eGFR results for a patient who fulfilled the inclusion 
criterias. To these GPs were sent a questionnaire collecting information on their 
assessment of the patient (the youngest patient was chosen if a physician had multiple 
patients). The questionnaire evaluated the abilities of the GP to categorize the 
patient’s renal function and what changes in creatinine and eGFR were considered 
clinically important or would lead to referral of the patient to nephrology or internal 
medicine care. Furthermore, we explored what examinations had been carried out, 
relevant co-morbidity diagnosed and drug treatment of the patient. The questionnaire 
was pilot-tested by ten GPs. The study was designed in accordance with the 
guidelines of the Regional Committees for Medical and Health Research Ethics and 
the Norwegian Privacy Ombudsman for Research, and the patients and GPs were 
anonymous to the researchers. The theoretical CD for creatinine was calculated to be 
13%, assuming no systematic change between the two measurements, a z value of 
1.64 (95% confidence, one-sided test), a CVa of 2% (CVa from routine creatinine 
measurements at the two hospitals in Bergen and Stavanger) and a CVi of 5.3% (94). 
Using the CD for creatinine (±13%) in the MDRD formula (116), the calculated CDs 
for the eGFR results were 13% for impaired and 17% for improved renal function. 
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Results: Article III 
The response rate in the study described in Article III was 60%; 19 respondents were 
excluded since they were not the GP usually caring for the patient, leaving 210 GPs 
to be included. The median age of the patients was 63 years, 53% were females, and 
73% had some kind of co-morbidity [hypertension (60%), CVD (25%) or diabetes 
(20%)]. Creatinine values were 124 mol/l for the males vs 95 μmol/l for the females, 
whilst eGFR values were similar for the two genders: 52 vs 51 ml/min/1.73 m2. 
Overall, two-thirds of patients had a urine dip strip and/or a urinary albumin 
measurement. In total, 20% had two positive tests for urinary albumin (12%) and/or 
urine dip strip (13%), and this was defined as albuminuria. Of the 53 dip-strip-
negative patients, approximately half had a urinary albumin measurement, and 10 
(19%) were diagnosed with albuminuria. Of the 42 patients who were diagnosed with 
albuminuria, 95% had CVD, hypertension or diabetes, and 79% used ACEIs or 
ARBs. Even though all patients had CKD stage 3, only 27% (55/201 patients) were 
categorized by GPs as having moderately reduced renal function (stage 3); the 
classification was more likely to be correct in males. Median changes to signal 
improvement or deterioration in renal function, or to indicate referral were 14 (12%), 
20 (18%) and 40 (36%) μmol/l, respectively, for creatinine, and 8 (17%), 8 (17%) 
and 13 (26%) ml/min/1.73 m2 for eGFR. Albuminuria did not influence the 
classification or magnitude of the clinically meaningful changes stated. 
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ARTICLE IV – INTERPRETATION OF 
ALBUMIN:CREATININ RATIO AND ESTIMATED
GLOMERULAR FILTRATION RATE RESULTS BY 
LABORATORY PROFESSIONALS 
Subjects and methods 
A questionnaire was developed containing three case histories that mimicked a 
situation where a clinician contacted the laboratory to discuss renal parameter results 
in these patients. Case 1 depicted a male primary-care patient with hypertension, a 
creatinine value of 119 mol/l (reference range 60–105 μmol/l) and an eGFR of 
54 ml/min/1.73 m2, corresponding to CKD stage 3. The second case described a male 
primary-care patient with diabetes and an ACR result of 15 mg/mmol. The 
descriptions of the case histories were followed by questions regarding further 
investigations and the changes in serial results that would be considered to be 
clinically significant. The third case history represented a typical hospital situation: a 
57-year-old female patient with borderline reduced renal function who should 
commence a nephrotoxic chemotherapy treatment regime. Questions were posed 
regarding how her renal function should be monitored before and during treatment.  
The questionnaire and reminders were distributed in 2009 by mail to 76 
physicians working in Norwegian laboratories. In the Netherlands, the questionnaire 
was sent to 24 laboratory specialists as part of a regular external quality assurance 
programme that covers the interpretation of laboratory results. Tests suggested by the 
laboratory specialists were based on recommendations in international guidelines (5, 
6, 38-42), classified by the authors as either “useful” or “unnecessary”, and the 
number of laboratory specialists who suggested (based on the same guidelines) an 
“optimal test panel” for the primary-care patients was noted. For patient 1, the 
“optimal test panel” included repeating eGFR measurement and testing for 
albuminuria (urine dip-strip and/or urinary albumin or protein measurements). 
Screening for haematuria (dip-strip or sediment) was regarded as appropriate but not 
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a requirement. For patient 2, repeated urinary albumin testing and eGFR 
measurement were regarded an “optimal test panel”, whilst for patient 3, gold-
standard clearance testing (e.g. iohexol, iothalamate and Cr-EDTA clearances, but not 
creatinine clearance) (6), eGFR and testing for albuminuria (urine dip-strip and/or 
urinary albumin or protein measurements) were found to be useful. 
Results: Article IV 
The response rate in the study described in Article IV was 52%, and 52 participants 
were included. Less than 30% of respondents suggested performing an optimal test 
panel for the primary-care patients in cases 1 and 2. Based on the first case history, 
52% recommended retesting of eGFR and 69% advised a follow-up urinary albumin 
test in a diabetic patient with an elevated ACR. For creatinine and eGFR, the median 
changes considered to represent improvement or deterioration in renal function were 
similar to what could be calculated using CVi values from the literature (creatinine, 
14% and 14%, respectively; eGFR, 18% and 13%, respectively), whilst for the ACR 
(50% and 67%, respectively) the values were variable and lower than the calculated 
ones. In case 3, 23% would recommend an accurate clearance measurement to be 
performed before the patient started the nephrotoxic chemotherapy regime, and 8% 
would recommend this before every chemotherapy cycle. For all case histories, 
approximately 20% of suggested tests were regarded as unnecessary. 
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DISCUSSION OF THE METHODS USED 
Questionnaire-based research may be complicated by different biases, and the 
following section includes a discussion of the methods used and their validity. The 
first part evaluates internal validity, including a general discussion on how 
questionnaires may be used as research tools. This is followed by comments on how 
the questionnaires were designed, recruitment of participants, registration of 
responses to assure good-quality data (117) and the statistical analyses chosen. The 
second part assesses the external validity of our findings. 
INTERNAL VALIDITY 
The use of case histories and chart abstractions as research tools 
In this work we used questionnaires including one or up to several case histories 
(Articles I, II and IV) and a questionnaire for which data were extracted from patient 
files (Article III). There is currently debate regarding how to obtain reliable 
information on physician’s actions and knowledge. Direct observation is usually 
considered to be the gold-standard method, but this is often not feasible due to it 
being cumbersome, time-consuming and expensive. The presence of an observer, 
tape recorder or camera in the physician’s office may also bias the physician’s or 
patient’s actions. The use of patient vignettes or chart abstractions may be used as a 
substitute for direct observations, and several studies (including two reviews; (118, 
119) have evaluated the accuracy of these methods. It has been suggested that the use 
of case-history-based questionnaires leads to overreporting of actions compared to 
other approaches (118-120). However, patient vignettes are still regarded as an 
efficient and robust way of measuring a GP’s knowledge because measurements are 
standardized (i.e. all GPs have the same information) (121). In some newer studies, 
GPs were consulted by standardized patients whom they believed were real patients 
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(gold standard), and actions taken during the consultation were compared to chart 
abstractions (from the same consultation) and responses to a similar case history 
presented in a questionnaire. Vignettes were found to be a better tool for evaluating 
GPs’ actions than were chart abstractions (122-124), and were especially suited for 
evaluating variations in practice between different sites (122, 123). 
 Patient files include most of the GPs’ actions and assessments in different 
situations, but may not reflect their actual knowledge. Data abstracted from patient 
files are influenced by the great heterogeneity that may be seen between patients (e.g. 
resulting from differences in compliance, patient preferences and co-morbidities). 
Studies using different gold standards (e.g. standardized patients, trained observers or 
audio/video recording) have shown varying specificities (range 81–100%) and 
sensitivity (range 60–83%) for evaluating the follow-up and treatment of patients 
based on data from journal files, and in particular actions might be underreported 
(118, 125). However, a higher degree of validity was seen for the reporting of 
specific clinical actions, as done in Article III (118). 
Designing the questionnaires 
The case histories and questionnaires were carefully designed after exploring the 
literature of specialists in primary health care and clinical chemistry with long-term 
experience in designing questionnaires used among primary health-care physicians 
(126-136). For Articles I, II and IV, real patients were used as models for the case 
histories, whilst for Article III the questionnaire obtained data of one of the patients 
enlisted with a GP. The questionnaires were simple to complete, had a closed format 
to facilitate similar interpretation of the questions between GPs and included space 
for open-format comments. All questionnaires were peer reviewed by other 
researchers, and those used for Articles I–III were pilot-tested by GPs. 
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Recruitment of study subjects and data registration
The focus of the first survey (Articles I and II) was to elucidate the potential 
problems related to urinary albumin testing and to collect data from geographical 
areas with diverse medical traditions and organization of health care, in order to make 
the observations more robust and possibly highlight differences in the correct use and 
interpretation of the test. The inclusion of GPs was not related to the specific topic 
studied (urinary albumin testing), but rather to other factors (e.g. geographical 
location, laboratories used and participation in external quality assessment schemes). 
For Article III, the hospital laboratory databases were searched for eligible patients 
using defined inclusion criteria, and all identified patients were included (except in a 
few cases where GPs had more than one patient fulfilling the inclusion criteria, in 
which cases only the youngest patient was included). For Article IV, all registered 
Norwegian laboratory specialists as well as doctors specializing in clinical chemistry 
were eligible for the survey. Retired professionals or those known by the authors to 
work in other specialties were excluded. In the Netherlands, most clinical chemists 
have a scientific background and only a minority have medical training. The 
questionnaire was sent to 24 laboratory specialists as part of a regular external quality 
assurance programme that covers the interpretation of laboratory results. 
 In the first survey (Articles I and II), responses were registered by national 
collaborators into a custom-made Web-based application, accessible only with 
country-specific usernames and passwords. A detailed instruction manual including 
information on how responses should be interpreted was provided to assure that the 
data registration was similar in all countries. For Articles III and IV, all replies were 
registered by one person (K.M.A.), thereby assuring a similar interpretation of the 
responses. 
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Response rate 
The response rate was low for all of the surveys. This was expected for several 
reasons, not least because physicians often exhibit low survey response rates (126-
128, 137, 138). First, for Articles I and II it was necessary to use a somewhat longer 
questionnaire compared to what had been used previously by our group (127-129, 
131) due to the complexity of the issue. Second, studies have shown that less than 
30% of GPs follow the recommendation of annual screening for urinary albumin 
(138-142), indicating that this is an unfamiliar subject to most GPs. A higher 
response rate was seen for Article III (60%), probably due to the use of real patients 
and exploring the use of a well-known test (creatinine). The lower response rate 
obtained for Article IV may reflect that many laboratory specialists do not work 
primarily with renal parameters. In all of the surveys, the questions on CD had the 
lowest response rate (70–80% of responders; for Article IV this was only seen for the 
question related to the ACR). This question was simplified after pilot testing (Articles 
I and II), and similar wording was used in the subsequent questionnaires. The most-
likely reason for the low response rate is that physicians find these questions difficult 
to answer. 
 The relatively low response rate could have influenced the results. The 
characteristics of the participating Norwegian GPs (i.e. their age, gender, 
specialization in primary health care and working in group practice) were similar to 
those of Norwegian GPs in general (personal communication; Andres Taraldset, The 
Norwegian Medical Association), and it is unlikely that non-responders are more 
skilful or have more knowledge about laboratory and clinical issues related to renal 
disease compared to the responders. Thus, if a higher response rate had been 
obtained, a larger variation within the results may have been expected; our findings 
should therefore be interpreted as “best practice” data. 
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Statistical analyses 
For all articles robust and well-known statistical analysis techniques (Student’s t-test 
and chi-square test) were used to evaluate differences between relevant groups in 
continuous or categorical variables. McNemar’s test was used to evaluate differences 
between proportions in paired samples (Article II). Multiple logistic or linear 
regression was determined to be applicable to exclude possible confounding effects 
exerted by the different dependent variables on the outcomes measured. Statistical 
analyses were performed using SPSS versions 14.0 to 18.0, and the level of statistical 
significance level was set at p<0.05. 
EXTERNAL VALIDITY 
The data presented in Articles I and II were obtained from different areas of Europe. 
It seems reasonable to assume that urinary albumin testing would be used less in 
health-care systems with less resources, and therefore our data might not be 
applicable to developing countries. The data in Article III were collected in two areas 
of Norway; whether these findings are representative of other countries remains to be 
determined. However, this study was designed to evaluate GPs’ actions related to 
renal disease when measurement of the eGFR had been implemented without a 
special educational programme or comments regarding the results from laboratory 
specialists. Changes in the laboratory protocol or reporting algorithms are usually 
implemented this way, and our findings may therefore be generalized to similar 
situations. The last article included laboratory specialists from two European 
countries. No statistical differences were found between the data obtained in Norway 
and the Netherlands; similar findings regarding the evaluation of laboratory 
specialists’ interpretation of laboratory results have also been shown by others (111-
114). These results are thus likely to be valid for other regions, at least in developed 
countries. 
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DISCUSSION OF THE RESULTS 
This section focuses on how knowledge related to urinary albumin and eGFR may 
affect a physician’s actions, and how misinterpretation of the test results may affect 
the utility of laboratory analysis results. The last part of the section focuses on 
informational strategies related to the implementation of new laboratory test 
procedures. 
Changing the indications or procedure for an established laboratory test 
An obstacle to optimal test utilization demonstrated by our findings was a lack of 
knowledge related to renal parameters amongst both laboratory staff and GPs. The 
data from primary health-care showed that albuminuria testing was more common in 
diabetic than in (for example) hypertensive or CKD patients (Articles II and III), and 
that relatively few laboratory specialists would recommend albuminuria testing in a 
hypertensive patient suspected of having CKD (Article IV). This is probably due to 
this laboratory procedure having been recommended for decades in diabetic patients, 
whilst its use is fairly new for hypertensive or CKD patients (32, 143, 144). A 
relatively low percentage of both GPs (62%) and laboratory specialists (69%; Articles 
I and IV) would suggest that a positive urinary albumin result is confirmed, as 
recommended by guidelines due to the large biological variation for this constituent. 
This could result in both false-positive and false-negative albuminuria diagnoses. 
 Articles I and IV demonstrate that many hospital laboratories perform or 
recommend suboptimal laboratory procedures for the assessment of urinary albumin, 
and Article III indicates that insensitive urine protein tests are often used in primary 
health care. Changes in the recommended procedure for performing a well-known 
analysis (i.e. from measuring urinary albumin after 24-hour urine collections to 
measuring the ACR in a morning sample) may be impeded for various reasons. First, 
guidelines might not be updated. In France, 80% of GPs would use 24-hour 
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collections for albuminuria testing (Article I), which is not necessary but can 
probably be explained by the local guidelines still recommending this (145). 
 Second, even if the optimal procedure is recommended on a national basis, 
local laboratories may not offer it, or else GPs may use POCT instruments that are 
not capable of performing the new procedure. Article I describes how GPs in France 
and Spain (mostly using hospital laboratories) were accustomed to albumin results 
reported as mg/24 hours reflecting that timed collections were offered by the 
laboratories. This assumption is strengthened by the finding that GPs who performed 
confirmatory testing in hospital laboratories used timed collections, as opposed to 
those GPs performing confirmatory testing in the office laboratory preferring the 
ACR. The use of the ACR was highest in Scandinavia. In Norway and Sweden, 
POCT instruments were common, and approximately two-thirds of those reporting 
the type of in-office instrument used had an ACR instrument (Article I). In Denmark, 
in-office testing is not common, but a high frequency of ACR use was still recorded. 
Both approaches (in-office or hospital testing) may therefore be adequate, depending 
on the availability of the optimal test procedure. 
 The use of different practices in different countries indicates that changing the 
indications or test procedure after a test is implemented is a difficult and slow 
process. After auditing the current practice, we sent a feedback report to all 
participants that showed their results and gave an update on the use and interpretation 
of urinary albumin results. The aim of this was to increase GPs’ knowledge regarding 
the subject and its effect may be evaluated in a later study. Actions should be taken 
by the relevant medical societies to inform users of laboratory analyses or 
laboratories about current evidence-based recommendations. Another strategy that 
has been proven to increase the use of routine laboratory tests (e.g. urinary albumin) 
is increased reimbursement for performing the most relevant test procedure (146). 
This decision is in the hands of health-care authorities, but could also be promoted by 
the medical and laboratory societies. 
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Information strategy for implementing new reporting algorithms for 
laboratory tests 
The reporting of eGFR results is recommended to facilitate an earlier diagnosis of 
CKD, and is assumed to be especially useful in populations with lower muscle mass 
(e.g. women and the elderly) who might have creatinine results within the normal 
range even if reduced renal function has developed. Article III shows that CKD was 
identified less in subjects with normal or only slightly elevated creatinine values (i.e. 
women), indicating that the continued reporting of creatinine with eGFR results in 
CKD stage 3 might be counterproductive with regard to facilitating an early diagnosis 
of CKD (147). An information newsletter was provided by the laboratories when 
eGFR reporting was implemented, as is usual when Norwegian hospital laboratories 
change procedures or protocol, and an article explaining the interpretation of eGFR 
results was published in the Journal of the Norwegian Medical Association (148). It 
was clearly demonstrated that this was not sufficient to inform GPs, and so more 
substantial educational efforts seem necessary (88, 101, 149). 
 A simple way of communicating the meaning of laboratory results to GPs 
could be to produce interpretive comments that are automatically reported along with 
the test result. Such an approach has been attempted for eGFR, and has led to a 
substantial increase in the rates of referral of CKD patients (87). In this way 
laboratories could act as an informational channel to GPs, thus efficiently facilitating 
an increased referral or use of routine urinary albumin testing in CKD patients. 
However, as demonstrated by the study described in Article IV and by earlier studies 
(111-114), laboratory professionals may offer misleading advice regarding the 
interpretation of common laboratory tests, and probably need guidance about 
performing such a task. Before a commenting procedure is implemented, it should be 
discussed within the relevant professional societies (which for eGFR would at least 
include clinical chemists and nephrologists), and any comments or reporting 
algorithms suggested would benefit from being pilot-tested. 
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 Such preparations prior to recommending a change may seem extensive, but 
all of the articles included in this dissertation indicate that changing established 
laboratory procedures or establishing new ones is a slow and difficult process. As a 
consequence, guidelines and position statements recommending new test procedures 
or reporting algorithms for laboratory tests would benefit from including clear and 
detailed strategies that facilitate the implementation of these changes. 
Consequences of misinterpretation related to urinary albumin testing 
More information on mortality and the progression of renal disease could usually be 
obtained from the presence of albuminuria than from the eGFR value itself (11-13), 
and urinary albumin investigations are recommended in all diabetic or CKD patients 
(5, 6, 39-41). All CKD or diabetic patients with albuminuria should be treated with 
ACEIs or ARBs (5, 6, 40, 41, 150), and Article II describes that a diagnosis of 
albuminuria results in GPs intensifying the treatment of a diabetic patient. It is 
therefore possible that the insufficient use of urinary albumin investigations in a 
substantial number of CKD patients or patients at risk of CKD that was demonstrated 
in Articles II and III could lead to inadequate treatment and an increased risk of 
complications. 
Chronic kidney disease staging and applicability in clinical practice 
The data presented in Article III show that most of the GPs did not interpret eGFR 
results according to the CKD classification system. However, that staging system has 
been criticized for not reflecting the clinical course of renal disease (8) since 
albuminuria, which is a more powerful prognostic predictor of the progression of 
renal damage (9, 11-13), is not included. Most GPs probably categorize renal disease 
according to their clinical experience, and since only 20% of patients included for 
Article III had albuminuria, GPs may have experienced that most of these patients 
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have a relatively stable renal function. This could explain why they did not find it 
appropriate to use the term “moderately reduced” to describe the patients’ renal 
function. An update of the CKD system to include albuminuria (8, 15, 16), thereby 
improving its agreement with the clinical course of renal disease and clinical 
experience, is supported by our findings. 
Interpretation of consecutive test results 
One of the main focus in this work was to ascertain the magnitude of changes in test 
results that GPs considered necessary to signal an important change in the patient’s 
clinical condition. There were large discrepancies between GPs, and many physicians 
denoted higher values than the CD calculated using the method suggested by Fraser 
and Harris (55). The great heterogeneity and the lower response rate to these 
questions show that the GPs had very diverse experiences, and that it is difficult to 
suggest such values, even for well-known patients. One reason is that the confidence 
intervals that GPs use when interpreting changes in test results (e.g. 80% or 99%) 
may differ from the 95% confidence intervals often used when calculating CD values. 
If more than two results are included in the series of test results evaluated (common 
in primary health care), this should (at a given level of confidence) lead to action as a 
result of smaller changes compared to if only two results are evaluated. A large 
variance in responses was seen when clinical chemists (who are accustomed to 
calculating CD) were asked to denote important changes in the ACR compared to 
creatinine and eGFR values. Our findings reflect that the information on CD is either 
limited or heterogeneous in the scientific literature (as for the ACR), or that the 
concept may be unknown to the respondents (especially in primary health care), since 
it is not communicated in guidelines or Web-based information tools. 
 One important limitation of the concept of CD is highlighted by our findings. 
The clinically important changes reported by GPs are probably not based on 
calculations or statistics, but rather on their clinical experience; that is, the outcomes 
of earlier patients who experienced similar changes in serial values. The CD is 
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defined as the minimum difference needed between two consecutive results to be 
certain (with a specified level of confidence) that the results are truly different, and 
that the difference is not due only to analytical variation and biological (CVa and 
CVi). Even so, in clinical practice, not all changes exceeding the calculated CD 
values are important because only changes that are associated with an adverse or 
improved outcome (as defined by clinical outcome studies) are important. Clinically 
significant changes may therefore occur both outside and within the limits of the 
calculated CD, depending on the constituent measured and the disease monitored. 
The probability for the change to represent an important change in the patient’s 
situation (i.e. improved or adverse outcome) may be calculated in a model including 
differences between two consecutive test results, prevalence of the disease (or 
prevalence of an improvement in the condition) monitored, and analytical variation of 
the constituent measured (56). This information could be useful when clinicians are 
interpreting repeat test results, and the consequences of making such information 
available to clinicians should be explored in future research studies. 
Setting analytical goals based on clinicians’ anticipation of significant 
clinical changes 
Using the CDs stated by doctors, it is possible to calculate the minimum analytical 
imprecision (assuming a zero bias between consecutive test results) anticipated by 
GPs, and compare this to what it is actually possible to achieve using POCT or 
hospital instruments. This was done in Article I because GPs conducted urinary 
albumin measurements in their office, and therefore the analytical quality of the 
instruments is important. We found that in most cases the GPs’ expectations were in 
line with what could be obtained if an 80% CI was used, and this is probably 
sufficient for clinical practice. 
48
MAIN CONCLUSIONS 
Our data suggest that the following features related to albumin and the eGFR have 
not been acknowledged by or conveyed to GPs: 
• Guidelines on diagnosing microalbuminuria are only partially followed. Timed 
collections or spot samples measuring urinary albumin concentration still 
dominate in some areas. Repeat testing after obtaining a positive result is 
conducted by one-half to two-thirds of physicians, and anticipated CD values 
are lower than those calculated based on CVa and CVi. 
• The medical treatment of diabetic patients after a diagnosis of 
microalbuminuria is currently insufficient when compared to guideline 
recommendations. 
• CKD stage 3 patients are insufficiently examined for albuminuria and appear 
to be referred to hospital care after larger eGFR declines than are 
recommended by the guidelines. 
• ACR and eGFR values from diabetic or hypertensive patients are interpreted 
differently by laboratory specialists, and this could result in different advice 
being offered to clinicians, which again may adversely affect patient care. 
As revealed by our data the reasons behind the insufficient use and interpretation of 
urinary albumin and eGFR results may be the conflicting or suboptimal 
recommendations provided by guidelines, inadequate educational efforts when 
implementing new or changing established test procedures, incongruence between 
GPs’ clinical experience and the recommendations, and limited research data on some 
issues. This may ultimately reduce the quality of health care provided to primary-care 
CKD patients. 
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FUTURE PERSPECTIVES 
The following further work would be useful to improve the quality of laboratory-
related recommendations and communications: 
• Evaluating whether the feedback report (including an update on the use and 
interpretation of urinary albumin) that was sent to all respondents for Articles I 
and II has improved GPs’ knowledge related to the use and interpretation of 
urinary albumin results. 
• Examining the way in which commenting of eGFR results may affect the 
follow-up and treatment of primary health-care CKD patients. 
• Determining how recommendations from international clinical chemistry 
societies may be better conveyed to laboratory specialists working in local 
clinical chemistry laboratories. 
• Exploring how to improve the communication between laboratory specialists 
and clinicians. 
• Developing a database including clinically significant changes for common 
laboratory tests that combines information from clinical outcome studies (e.g. 
studies providing information on the magnitude of changes signalling adverse 
or improved outcomes) and CD (changes that might be seen in a stable 
situation) should be established, and its subsequent effects on clinical practice 
should be evaluated. 
• Generating a checklist stating what information should be included on 
laboratory analyses in clinical guidelines. Examples of such information could 
be what specimens are suitable to use, important pre-analytical conditions, 
major analytical interference, biological variations, clinically important 
changes in consecutive results, the need for follow-up testing after obtaining a 
positive result and strategies for the implementation of new test algorithms. 
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